Tuesday, May 20, 2025
spot_img

Kaldalón hf.: Trading Statement for Q1 2025

Reference is made to the Company’s announcement dated 3 December 2024 and to the financial calendar of Kaldalón hf.

As previously disclosed, the Board of Directors of Kaldalón hf. has approved the publication of additional interim information to be released between the Company’s half-year and full-year financial reports. These interim disclosures will take the form of unaudited trading statements for the first and third quarters, providing insight into the Company’s financial performance, balance sheet position, and key developments during the reporting periods.

Attached is the Company’s trading statement for the first quarter of 2025.

For further information, please contact:
Jón Þór Gunnarsson, CEO, Kaldalón hf.
[email protected]

Attachment

  • Kaldalon_trading statement Q1-2025 (EN)

Powered by SlickText.com

Hot this week

AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025

IRVINE, Calif., May 19, 2025 (GLOBE NEWSWIRE)...

Medicare Boosts Reimbursement for Oncocyte’s Flagship Technology

New price of $2,753 for the GraftAssureCore™ assay increases total...

Topics

spot_img

Related Articles

Popular Categories

spot_img